The Neuroimaging Core has experienced considerable growth and continuing productivity during the past funding cycle. The Core supports all routine clinical and research ADC neuroimaging examinations, funded imaging projects and scientific collaborations, and multi-institutional neuroimaging training. The Core has contributed to image acquisition, image registration, anatomical validation, and image analysis projects. Image analysis methods were extended from human imaging to transgenic mouse brain. Core resources were directly responsible for many ADC accomplishments by contributing to research teams innovative image analysis software and making the applications user friendly. Core's growth is in large measure attributable to the think tank atmosphere created by a dedicated multidisciplinary faculty. The proposed plan aims to continue Core's hardware and software support for research projects, development and validation of new MRI and PET imaging modalities for in vivo functional human imaging, routine post mortem MRI imaging, customized mouse imaging protocols that includes histological validation, uniform acquisition, investigator training, and quality control of all studies. These activities will improve the accuracy of AD diagnosis and lead to mechanistic models of brain changes in normal aging and dementia.
The proposed plan for the Neuroimaging Core is to continue support for the clinical scanning of ADC patients and for research projects. The cores mission includes: development and validation of MRI and PET imaging modalities for in vivo functional human imaging. This is realized by routine post mortem MRI imaging with histological validation of imaging findings, correlated CSF studies, customized mouse MRI imaging protocols, uniform longitudinal scan acquisitions, investigator training, novel image analysis software development, and quality control of all studies. These activities will continue to improve the accuracy of the advance AD diagnosis and contribute to identifying and testing mechanisms of brain change in normal aging and dementia.
|Wang, Tingyan; Qiu, Robin G; Yu, Ming (2018) Predictive Modeling of the Progression of Alzheimer's Disease with Recurrent Neural Networks. Sci Rep 8:9161|
|Herline, Krystal; Prelli, Frances; Mehta, Pankaj et al. (2018) Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model. Alzheimers Res Ther 10:54|
|Agogo, George O; Ramsey, Christine M; Gnjidic, Danijela et al. (2018) Longitudinal associations between different dementia diagnoses and medication use jointly accounting for dropout. Int Psychogeriatr 30:1477-1487|
|Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360|
|Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340|
|Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872|
|Goñi, Fernando; Martá-Ariza, Mitchell; Herline, Krystal et al. (2018) Anti-?-sheet conformation monoclonal antibody reduces tau and A? oligomer pathology in an Alzheimer's disease model. Alzheimers Res Ther 10:10|
|Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679|
|Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104|
|Schaffert, Jeff; LoBue, Christian; White, Charles L et al. (2018) Traumatic brain injury history is associated with an earlier age of dementia onset in autopsy-confirmed Alzheimer's disease. Neuropsychology 32:410-416|
Showing the most recent 10 out of 604 publications